🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the fight against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are increasing globally, with figures suggesting more than 82 million instances per year. Notably increased rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the reality of rising global incidence, escalating drug resistance and the very limited available drugs presently on offer.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". Ongoing monitoring showed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, gained clearance in close succession. This medication, which is also used to treat UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The charitable organization GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This approval represents a significant shift in the management of highly resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Research Study Outcomes and Global Access

According to results detailed in a major medical journal, the new drug cured more than 90% of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which uses two antibiotics. The study included hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the rights to license and sell the drug in many developing nations.

Doctors treating patients have voiced optimism. Access to a one-pill regimen such as this is seen as a "game-changer" for gonorrhoea control. This is viewed as essential to lessen the impact of the disease for people and to stop the proliferation of untreatable gonorrhoea globally.